ReviewFrontiers in bioengineering and biotechnology2026
Nanostructure driven innovation in diabetes: from enhanced biosensing to smart therapeutic delivery.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus continues to be a global public health concern, owing to its increasing incidence, complex etiology, and the limitations of standard therapy regimens. Conventional therapeutic strategies often face several limitations including poor bioavailability, frequent administration, and absence of real-time blood sugar regulation. Recent advancement of smart nanotechnology has provided new opportunities for prevention, diagnoses, and management of diabetes as a part of smart health concept and precision medicine. This review highlights the recent trends in the design and application of nanotechnology for managing diabetes specifically focusing on two areas, glucose monitoring and drug delivery. Novel drug delivery systems are revolutionizing diabetes treatment, providing better pharmacokinetic control, adherence of patients, reduction of side effects, and target/stimuli responsive therapy. Recent developments in this area include sustained release implants and depots for extended periods of glycemic control; nanoparticles and liposomes for improved oral absorption and protection of insulin against enzymatic hydrolysis; transdermal and microneedles for minimal invasive delivery of insulin and peptides; inhalable dosage forms for faster systemic absorption; and glucose responsive 'smart' devices which deliver drugs only when required due to hyperglycemia. The use of nanotechnology-based biosensors and wearable devices has enabled the development of glucose monitoring based on their improved sensitivity, specificity, and integration into digital healthcare applications. Nanotechnology, coupled with artificial intelligence, and real-world health data, enhances personalized diabetes management through predictive monitoring and adaptive insulin delivery systems. Despite tremendous achievements, still some concerns persist, related to clinical translation, biosafety issues, and regulations. With continued interdisciplinary research that integrates the materials science, bioengineering, and clinical medicine, smart nanotechnology holds substantial promise to shift diabetes care, enabling an improvement in diabetic treatment from symptomatic to a physiologically sounder approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.